Allergan, Inc. Announces Completion of SkinMedica, Inc. Acquisition

  Allergan, Inc. Announces Completion of SkinMedica, Inc. Acquisition

Business Wire

IRVINE, Calif. -- December 19, 2012

Allergan, Inc. (NYSE:AGN) today announced that it has completed the
acquisition of SkinMedica, Inc. Under the terms of the agreement, which was
first announced on November 16, 2012, Allergan paid approximately $350 million
(subject to certain adjustments) for the business, which includes a variety of
"physician dispensed" non-prescription aesthetic skin care products and
prescription products. In connection with the closing of the transaction,
SkinMedica spun out its Colorescience aesthetic make-up business. Allergan
plans to operate SkinMedica as a separate global business based out of
SkinMedica’s current headquarters in Carlsbad, CA.

“The acquisition of SkinMedica reinforces our commitment to fueling growth
through a combination of internal investment in research and development and
leveraging external opportunities,” said David E.I. Pyott, Chairman of the
Board, President and Chief Executive Officer, Allergan. “Today marks a
significant achievement for Allergan, as our acquisition of SkinMedica will
enable us to assume a leadership position in the ‘physician dispensed’ topical
aesthetics category and will further strengthen our leadership position in the
facial aesthetics market by expanding our product portfolio to better meet the
needs of physicians and their patients.”

About Allergan, Inc.

Allergan is a multi-specialty health care company established more than 60
years ago with a commitment to uncover the best of science and develop and
deliver innovative and meaningful treatments to help people reach their life’s
potential. Today, we have approximately 10,500 highly dedicated and talented
employees, global marketing and sales capabilities with a presence in more
than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals,
biologics, medical devices and over-the-counter consumer products, and
state-of-the-art resources in R&D, manufacturing and safety surveillance that
help millions of patients see more clearly, move more freely and express
themselves more fully. From our beginnings as an eye care company to our focus
today on several medical specialties, including eye care, neurosciences,
medical aesthetics, medical dermatology, breast aesthetics, obesity
intervention and urologics, Allergan is proud to celebrate more than 60 years
of medical advances and proud to support the patients and physicians who rely
on our products and the employees and communities in which we live and work.
For more information regarding Allergan, go to: www.allergan.com.

Allergan Forward-Looking Statements

This press release contains "forward-looking statements," including, but not
limited to, the statements by Mr. Pyott and other statements regarding the
expected benefits of the transaction and other statements regarding Allergan’s
planned operation of SkinMedica. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could vary
materially from Allergan's expectations and projections. Risks and
uncertainties include, among other things, general industry and market
conditions; technological advances and patents attained by competitors;
challenges inherent in the research and development and regulatory processes;
challenges related to product marketing, such as the unpredictability of
market acceptance for new products and/or the acceptance of new indications
for such products; inconsistency of treatment results among patients; general
economic conditions; and governmental laws and regulations affecting domestic
and foreign operations. Allergan expressly disclaims any intent or obligation
to update these forward-looking statements except as required by law.
Additional information concerning the above referenced risk factors and other
risk factors can be found in Allergan's public periodic filings with the
Securities and Exchange Commission, including the discussion under the heading
"Risk Factors" in Allergan's 2011 Annual Report on Form 10-K and subsequent
Quarterly Reports on Form 10-Q. Additional information about Allergan is
available at www.allergan.com or you can contact the Allergan Investor
Relations Department by calling 714-246-4636.

Contact:

Allergan Contacts:
Bonnie Jacobs, (856) 912-9965 (media)
jacobs_bonnie@allergan.com
Cathy Taylor (949) 293-4453 (media)
taylor_cathy@allergan.com
Jim Hindman (714) 246-4636 (investors)
Joann Bradley (714) 246-4766 (investors)
David Nakasone (714) 246-6376 (investors)
 
Press spacebar to pause and continue. Press esc to stop.